Hindi nagbibigay ng serbisyo ang XM sa mga residente ng Estados Unidos.

Hindi nagbibigay ng serbisyo ang XM sa mga residente ng Estados Unidos.
G
G

GSK

Balita

Reuters - 6 araw ang nakaraan

German panel endorses GSK, Pfizer RSV vaccines for elderly

German panel endorses GSK, Pfizer RSV vaccines for elderly FRANKFURT, Aug 8 (Reuters) - Germany's influential vaccine advisory panel said on Thursday that everyone in the country who is 75-years old or more should receive one of two new vaccines against the common respiratory infection RSV. The panel of independent experts known as STIKO said in a statement that one shot, either Pfizer's PFE.N Abrysvo or Arexvy by GSK GSK.L , should be administered ideally in September or October before the cold
A
G
P
S
Reuters - 1 linggo ang nakaraan

UK Stocks-Factors to watch on August 8

UPDATE 1-UK Stocks-Factors to watch on August 8 Adds new items, updates futures Aug 8 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening lower on Thursday, with futures FFIc1 down 0.3%. * BARRATT-REDROW DEAL: UK's competition regulator said its phase 1 review into homebuilder Barratt's BDEV.L 2.52 billion pound ($3.21 billion) all-stock deal to buy smaller rival Redrow RDW.L had raised concerns in the local area around a Barratt development.
A
A
B
B
B
B
F
G
I
I
P
P
R
R
S
S
Reuters - 1 linggo ang nakaraan

UK Stocks-Factors to watch on August 8

UK Stocks-Factors to watch on August 8 Aug 8 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening lower on Thursday, with futures FFIc1 down 0.5%. * GSK: The third trial over claims that discontinued heartburn drug Zantac ended in a mistrial when jurors could not agree about whether pharmaceutical company Boehringer Ingelheim was responsible for an Illinois man's cancer.
A
A
B
B
B
D
F
G
H
I
I
L
P
P
P
R
S
S
U
Reuters - 1 linggo ang nakaraan

Third trial over Zantac cancer claims ends with hung jury

UPDATE 1-Third trial over Zantac cancer claims ends with hung jury Adds response from plaintiff's attorney in paragraphs 2-3 By Brendan Pierson Aug 7 (Reuters) - The third trial over claims that discontinued heartburn drug Zantac ended in a mistrial on Wednesday when jurors could not agree about whether pharmaceutical company Boehringer Ingelheim was responsible for an Illinois man's cancer.
G
P
S
Reuters - 1 linggo ang nakaraan

Third trial over Zantac cancer claims ends with hung jury

Third trial over Zantac cancer claims ends with hung jury By Brendan Pierson Aug 7 (Reuters) - The third trial over claims that discontinued heartburn drug Zantac ended in a mistrial on Wednesday when jurors could not agree about whether pharmaceutical company Boehringer Ingelheim was responsible for an Illinois man's cancer, according to the plaintiff's lawyer.
G
P
S
Reuters - 1 linggo ang nakaraan

Drugmaker Abbott India's Q1 profit climbs on higher sales, price hikes

Drugmaker Abbott India's Q1 profit climbs on higher sales, price hikes BENGALURU, Aug 7 (Reuters) - Drugmaker Abbott India ABOT.NS reported a rise in first-quarter profit on Wednesday, helped by higher sales and price hikes. The company, which makes the popular antacid medicine Digene, said its profit rose to 3.28 billion rupees ($39.1 million) for the quarter ended June 30, a 13% rise from last year.
A
G
P
Reuters - 1 linggo ang nakaraan

Jefferies cuts SOBI to 'hold' as competition weighs

BUZZ-Jefferies cuts SOBI to 'hold' as competition weighs ** Jefferies cuts Swedish Orphan Biovitrum SOBIV.ST to "hold" from "buy", citing increasing competition pressure for the Swedish drug maker ** Brokerage sees Merck's MRK.N positive data for antibody against lung infections caused by respiratory syncytial virus (RSV), clesrovimab, as a downsid
G
S
Reuters - 1 linggo ang nakaraan

UK Stocks-Factors to watch on Aug 6

UK Stocks-Factors to watch on Aug 6 Aug 6 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening higher on Tuesday, with futures FFIc1 up 1.2%. * IHG: Holiday Inn-owner InterContinental Hotels Group IHG.L reported a 3.2% rise in revenue per available room (RevPAR) in the second quarter as a strong rebound in the United States offset weakness in China.
B
G
H
T
U
Reuters - 1 linggo ang nakaraan

GSK wins latest trial over Zantac cancer claims

GSK wins latest trial over Zantac cancer claims By Brendan Pierson Aug 5 (Reuters) - GSK GSK.L won the latest trial over claims that discontinued heartburn drug Zantac caused cancer, as a jury on Monday found that the drug was not responsible for an Illinois woman's illness, a company spokesperson said. Carrie Joiner had alleged in her lawsuit in state court in Chicago that she developed colorectal cancer from a carcinogenic contaminant called NDMA found in the once-blockuster drug.
G
P
S
Reuters - 2 linggo ang nakaraan

India's GlaxoSmithKline Pharma posts higher Q1 adjusted profit on strong demand

India's GlaxoSmithKline Pharma posts higher Q1 adjusted profit on strong demand BENGALURU, Aug 2 (Reuters) - India's GlaxoSmithKline Pharmaceuticals GLAX.NS reported a higher first-quarter adjusted profit on Friday, driven by strong demand for its generic drugs and vaccines. The Indian unit of British drugmaker GSK GSK.L reported a consolidated profit before tax and exceptional items of 2.49 billion rupees ($29.7 million) for the quarter ended June 30, compared with a profit of 1.64 billion rupe
A
G
P
Reuters - 2 linggo ang nakaraan

GSK Says FDA Expands Jemperli Approval

BRIEF-GSK Says FDA Expands Jemperli Approval Aug 2 (Reuters) - GSK plc GSK.L : FDA EXPANDS JEMPERLI APPROVAL JEMPERLI APPROVAL NOW INCLUDES MMRP/MSS TUMOURS Source text for Eikon: ID:nRSB8948Ya Further company coverage: GSK.L
G
Reuters - 2 linggo ang nakaraan

India economic, corporate events on August 2

DIARY- India economic, corporate events on August 2 BENGALURU, Aug 2 (Reuters) - Diary of India economic, corporate events on August 2. ECONOMIC, CORPORATE .BSE500 EVENTS: Start Date Start Time RIC Company Name Event Name 02-Aug-2024 NTS BRIT.NS Britannia Industries Ltd Q1 2025 Britannia Industries Ltd Earnings Release 02-Aug-2024 NTS GLAX.NS Glaxo
G
Reuters - 2 linggo ang nakaraan

Danske Bank, Greggs, HSBC

EUROPE RESEARCH ROUNDUP-Danske Bank, Greggs, HSBC Aug 1 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Danske Bank, Greggs, and HSBC, on Thursday. HIGHLIGHTS * Danske Bank DANSKE.CO : HSBC raises target price to DKK 258 from DKK 257 * Greggs GRG.L : Berenberg raises target price to 3600p from 3340p * HSBC HSBA.L : Berenberg raises target price to 870p from 830p * Kardex Holding AG KARN.S : Berenberg raises target price to CHF 260
A
A
A
A
A
B
B
C
C
C
D
F
G
G
H
L
T
W
A
D
S
Reuters - 2 linggo ang nakaraan

GSK plc reports results for the quarter ended in June - Earnings Summary

GSK plc reports results for the quarter ended in June - Earnings Summary GSK plc GSK.L reported quarterly adjusted earnings of 43 pence​​ per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of 39 pence. The mean expectation of eight analysts for the quarter was for earnings of 38 pence per share.
G
Reuters - 2 linggo ang nakaraan

GSK slips on vaccine sales miss; cuts vaccine sales outlook

BUZZ-GSK slips on vaccine sales miss; cuts vaccine sales outlook ** Shares of GSK GSK.L down 2.6% at 1,502 pence; top loser on the FTSE 100 index ** Posts a 9% miss in vaccine sales after Shingrix sales missed consensus due to the U.S. demand weakness including destocking and a weaker sales outside the U.S. according to Jefferies ** Sees vaccine sa
G
U
Reuters - 2 linggo ang nakaraan

GSK plc reports results for the quarter ended in January - Earnings Summary

GSK plc reports results for the quarter ended in January - Earnings Summary GSK plc GSK.N reported quarterly adjusted earnings of $1.10​​ per share for the quarter ended in January, higher than the same quarter last year, when the company reported EPS of 97 cents. The mean expectation of two analysts for the quarter was for earnings of 98 cents per share.
G
Reuters - 2 linggo ang nakaraan

Europe before the bell: appetite for tech, bank results

LIVE MARKETS-Europe before the bell: appetite for tech, bank results Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com EUROPE BEFORE THE BELL: APPETITE FOR TECH, BANK RESULTS Even though Microsoft MSFT.O failed to impress high Wall Street expectations, with growth in its cloud business falling a little short of what analysts had estimated, appetite for tech looked strong again on W
G
H
L
M
S
A
E
F
U
G
Reuters - 2 linggo ang nakaraan

UK Stocks-Factors to watch on July 31

UPDATE 1-UK Stocks-Factors to watch on July 31 Adds new items, updates futures July 31 - Britain's FTSE 100 .FTSE index is seen opening higher on Wednesday, with futures FFIc1 up 0 .8%. * GSK: British drugmaker GSK GSK.L raised its annual earnings and sales forecasts and posted second-quarter results that beat market expectations, boosted by its cancer and HIV portfolio.
F
G
H
R
T
Reuters - 2 linggo ang nakaraan

GSK Sees 2024 Turnover Growth Increase Of 7% To 9%

BRIEF-GSK Sees 2024 Turnover Growth Increase Of 7% To 9% July 31 (Reuters) - GSK plc GSK.L : GSK PLC - 2ND QUARTER RESULTS GSK: 2024 TURNOVER GROWTH INCREASE OF 7% TO 9% GSK - Q2 2024 DIVIDEND OF 15P DECLARED GSK SEES FY CORE OPERATING PROFIT GROWTH OF 11% TO 13% GSK SEES FY CORE EPS GROWTH OF 10% TO 12% (PREVIOUSLY 8% TO 10%) Source text for Eikon
G
Reuters - 2 linggo ang nakaraan

GSK shares fall after sales of top two vaccines disappoint

UPDATE 8-GSK shares fall after sales of top two vaccines disappoint Sales for top two vaccines disappoint Cuts vaccine outlook, cites US agency decision on RSV Shares fall as much as 2.2% Raises annual earnings, sales outlook for 2nd time this year Factors hitting vaccine sales are short-term: CEO Adds vaccines concerns from analyst call in paragraph 12 By Yadarisa Shabong and Maggie Fick July 31 (Reuters) - British drugmaker GSK GSK.L cut its forecast for 2024 vaccine sales on Wednesday after q
G
P
U

Kundisyon

Mga Patok na Assets

Disclaimer: Ang mga kabilang sa XM Group ay nagbibigay lang ng serbisyo sa pagpapatupad at pag-access sa aming Online Trading Facility, kung saan pinapahintulutan nito ang pagtingin at/o paggamit sa nilalaman na makikita sa website o sa pamamagitan nito, at walang layuning palitan o palawigin ito, at hindi din ito papalitan o papalawigin. Ang naturang pag-access at paggamit ay palaging alinsunod sa: (i) Mga Tuntunin at Kundisyon; (ii) Mga Babala sa Risk; at (iii) Kabuuang Disclaimer. Kaya naman ang naturang nilalaman ay ituturing na pangkalahatang impormasyon lamang. Mangyaring isaalang-alang na ang mga nilalaman ng aming Online Trading Facility ay hindi paglikom, o alok, para magsagawa ng anumang transaksyon sa mga pinansyal na market. Ang pag-trade sa alinmang pinansyal na market ay nagtataglay ng mataas na lebel ng risk sa iyong kapital.

Lahat ng materyales na nakalathala sa aming Online Trading Facility ay nakalaan para sa layuning edukasyonal/pang-impormasyon lamang at hindi naglalaman – at hindi dapat ituring bilang naglalaman – ng payo at rekomendasyon na pangpinansyal, tungkol sa buwis sa pag-i-invest, o pang-trade, o tala ng aming presyo sa pag-trade, o alok para sa, o paglikom ng, transaksyon sa alinmang pinansyal na instrument o hindi ginustong pinansyal na promosyon.

Sa anumang nilalaman na galing sa ikatlong partido, pati na ang mga nilalaman na inihanda ng XM, ang mga naturang opinyon, balita, pananaliksik, pag-analisa, presyo, ibang impormasyon o link sa ibang mga site na makikita sa website na ito ay ibibigay tulad ng nandoon, bilang pangkalahatang komentaryo sa market at hindi ito nagtataglay ng payo sa pag-i-invest. Kung ang alinmang nilalaman nito ay itinuring bilang pananaliksik sa pag-i-invest, kailangan mong isaalang-alang at tanggapin na hindi ito inilaan at inihanda alinsunod sa mga legal na pangangailangan na idinisenyo para maisulong ang pagsasarili ng pananaliksik sa pag-i-invest, at dahil dito ituturing ito na komunikasyon sa marketing sa ilalim ng mga kaugnay na batas at regulasyon. Mangyaring siguruhin na nabasa at naintindihan mo ang aming Notipikasyon sa Hindi Independyenteng Pananaliksik sa Pag-i-invest at Babala sa Risk na may kinalaman sa impormasyong nakalagay sa itaas, na maa-access dito.

Babala sa Risk: Maaaring malugi ang iyong kapital. Maaaring hindi nababagay sa lahat ang mga produktong naka-leverage. Mangyaring isaalang-alang ang aming Pahayag sa Risk.